Table 3.
Comparison of baseline laboratory parameters and scores between the survivors and the patients who died within 3 months
| Parameter | Total patients (n = 171) | Survivors (n = 147) | Patients who died (n = 24) | Survivor vs. died p value | 95% CI |
|---|---|---|---|---|---|
| Haemoglobin, g/dL | 10.55 (13.29) | 10.64 (13.29) | 8.57 (9.51) | 0.510 | −2.36 to 0.09 |
| WBC count, ×103/mm3 | 8.57 (45.71) | 8.54 (36.16) | 12.36 (42.14) | 0.001 | 3.33 to 8.54 |
| Platelet count, ×103/mm3 | 120 (381.05) | 120 (381.05) | 115 (340.59) | 0.707 | −36.89 to 22.26 |
| Total serum bilirubin, mg/dL | 4.8 (34.8) | 4.64 (34.8) | 9.41 (33.09) | 0.004 | 1.87 to 8.48 |
| INR | 1.73 (3.72) | 1.64 (3.55) | 2.64 (3.18) | <0.001 | 0.74 to 1.29 |
| Serum albumin, g/dL | 2.17 (3.23) | 2.32 (3.23) | 1.63 (2.45) | <0.001 | −0.88 to −0.32 |
| Serum AST, IU/L | 94 (3,926) | 86 (3,926) | 129 (3,211) | 0.054 | −191.28 to 398.97 |
| Serum ALT, IU/L | 42 (3,537) | 42 (3,537) | 45 (3,465) | 0.150 | −257.01 to 368.13 |
| Serum ALP, IU/L | 111 (463) | 111 (347) | 114 (426) | 0.285 | −8.60 to 52.92 |
| Serum sodium, mmol/L | 133.3 (29.01) | 133.6 (23.28) | 130.15 (29) | 0.006 | −5.18 to −1.20 |
| Serum potassium, mmol/L | 4.22 (5.29) | 4.2 (4.62) | 4.4 (4.65) | 0.626 | −0.51 to 0.24 |
| Serum creatinine, mg/dL Prognostic score | 1.12 (10.68) | 1.1 (10.68) | 2.17 (6.29) | <0.001 | 0.63 to 1.87 |
| CTP | 10 (10) | 9 (10) | 14 (3) | <0.001 | 3.12 to 5.02 |
| MELD | 21 (40) | 20 (32) | 32.5 (29) | <0.001 | 8.93 to 15.17 |
| MELD-Na | 24.46 (57) | 23.13 (53.83) | 42.67 (44.82) | <0.001 | 12.13 to 22.13 |
Data are presented as median (range). ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; INR, international normalized ratio; CTP, Child-Turcotte-Pugh; MELD, Model for End-Stage Liver Disease; WBC, white blood cell; Na, sodium.